Biorelevant Two-Stage In Vitro Testing for rDCS Classification and in PBPK Modeling-Case Example Ritonavir.
Amorphous solid dispersions (ASD)
Biopharmaceutical Classification System (BCS)
Developability
Dissolution
In silico modeling
In vitro models
Physiologically based pharmacokinetic (PBPK) modeling
Precipitation
SimCyp PBPK modeling
Supersaturation
Journal
Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
17
03
2020
revised:
30
04
2020
accepted:
30
04
2020
pubmed:
11
5
2020
medline:
22
6
2021
entrez:
11
5
2020
Statut:
ppublish
Résumé
Biorelevant two-stage in vitro testing is increasingly used as a tool for various applications in drug development. Three important applications of two-stage in vitro testing are the classification of weakly basic drug compounds as part of the refined Developability Classification System, the prediction of intraluminal drug concentrations in the gastrointestinal tract and the prediction of plasma concentration profiles using physiologically based pharmacokinetic modeling. For the weakly basic, antiretroviral drug ritonavir, two-stage testing is triggered as a customized investigation in the refined Developability Classification System classification process to assess whether the drug could supersaturate and precipitate when exposed to the steep change in pH that occurs during drug transfer from the stomach into the small intestine. It was shown that for 2 Norvir® formulations, a tablet and an oral powder formulation, the two-stage test yielded similar results to the more complex "transfer" model with regard to the supersaturation and precipitation behavior of these amorphous solid dispersion formulations. Furthermore, solubility and two-stage data were mechanistically modeled in the in vitro data Analysis Toolkit and the results used as input parameters for a physiologically based pharmacokinetic model built in the Simcyp Simulator.
Identifiants
pubmed: 32387425
pii: S0022-3549(20)30246-X
doi: 10.1016/j.xphs.2020.04.023
pii:
doi:
Substances chimiques
Ritonavir
O3J8G9O825
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2512-2526Informations de copyright
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.